TherapeuticsMD, Inc. (NASDAQ:TXMD) Sees Large Decrease in Short Interest

TherapeuticsMD, Inc. (NASDAQ:TXMD) saw a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 12,000 shares, a drop of 43.7% from the December 15th total of 21,300 shares. Currently, 0.1% of the shares of the company are short sold. Based on an average daily volume of 275,000 shares, the short-interest ratio is presently 0.0 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on TherapeuticsMD in a report on Tuesday. They issued a “hold” rating for the company.

TherapeuticsMD Trading Down 5.5 %

TXMD opened at $1.04 on Tuesday. The firm has a fifty day moving average price of $1.27 and a 200 day moving average price of $1.55. TherapeuticsMD has a 1 year low of $0.70 and a 1 year high of $2.75.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP increased its stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 636,622 shares of the company’s stock after acquiring an additional 101,282 shares during the quarter. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent reporting period. 30.74% of the stock is currently owned by hedge funds and other institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.